Bjørn Naume
0000-0002-6811-9476
Publication & Citation Trends
Publications
290 total
High tumor expression of CTLA4 identifies lymph node-negative basal-like breast cancer patients with excellent prognosis
Cited by 2
Semantic Scholar
Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy
Cited by 1
Semantic Scholar
Anti‐Her2 therapy patterns in metastatic breast cancer—Real‐world data suggest undertreatment
Cited by 2
Semantic Scholar
Single-cell analysis reveals tumour size as a key driver of immune cell profile alterations in primary breast tumours and corresponding lymph nodes
Cited by 1
Semantic Scholar
Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives.
Cited by 1
Semantic Scholar
Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE
Cited by 2
Semantic Scholar
Abstract P2-01-26: Carboplatin added to neoadjuvant chemotherapy in a randomized phase II study: Complex DNA based biomarkers predict response in hormone receptor positive and triple negative breast cancer
Cited by 0
Semantic Scholar
A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE).
Cited by 1
Semantic Scholar
Research Topics
Cancer Genomics and Diagnostics
(78)
Breast Cancer Treatment Studies
(75)
Cancer Cells and Metastasis
(69)
Cancer-related molecular mechanisms research
(24)
HER2/EGFR in Cancer Research
(24)
Affiliations
Oslo University Hospital
Universität Hamburg
University of Oslo
Universität Innsbruck
Breast Cancer Research Foundation